Inventprise Press Release Archive

Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate
January 2, 2024
New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation
November 10, 2022
Inventprise Inaugurates Manufacturing Facility for High-Capacity Supply of Pneumococcal Conjugate Vaccines
May 10, 2022
Inventprise Receives $30M, Appoints New CEO and Expands Corporate Board
April 7, 2022
Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials
November 10, 2021